145 related articles for article (PubMed ID: 33717264)
1. An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer.
Giampieri R; Cantini L; Del Prete M; Bittoni A; Giglio E; Mandolesi A; Maccaroni E; Lanese A; Meletani T; Baleani MG; Bisonni R; Scarpelli M; Berardi R
Oncol Lett; 2021 Apr; 21(4):267. PubMed ID: 33717264
[TBL] [Abstract][Full Text] [Related]
2. Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study.
Kroese TE; Takahashi Y; Lordick F; van Rossum PSN; Ruurda JP; Lagarde SM; van Hillegersberg R; Verhoeven RHA; van Laarhoven HWM
Eur J Cancer; 2023 Jan; 179():65-75. PubMed ID: 36509000
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
4. Impact of Sites of Metastatic Dissemination on Survival in Advanced Gastroesophageal Adenocarcinoma.
Wang X; Espin-Garcia O; Jiang DM; Allen MJ; Ma LX; Bach Y; Chen EX; Darling G; Yeung JC; Wong RKS; Veit-Haibach P; Kalimuthu S; Jang RW; Elimova E
Oncology; 2022; 100(8):439-448. PubMed ID: 35764050
[TBL] [Abstract][Full Text] [Related]
5. First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status.
Hwang JE; Kim HN; Kim DE; Shim HJ; Bae WK; Hwang EC; Cho SH; Chung IJ
Exp Ther Med; 2012 Oct; 4(4):562-568. PubMed ID: 23170106
[TBL] [Abstract][Full Text] [Related]
6. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy.
Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hoerner-Rieber J; König L; Kappes J; Thomas M; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
J Neurooncol; 2017 Aug; 134(1):205-212. PubMed ID: 28560661
[TBL] [Abstract][Full Text] [Related]
7. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis.
Guo X; Zhao F; Ma X; Shen G; Ren D; Zheng F; Du F; Wang Z; Ahmad R; Yuan X; Zhao J; Zhao J
BMC Cancer; 2019 Nov; 19(1):1125. PubMed ID: 31747911
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Seo S; Park SJ; Ryu MH; Park SR; Ryoo BY; Park YS; Na YS; Lee CW; Lee JK; Kang YK
Oncotarget; 2017 May; 8(20):33844-33854. PubMed ID: 27802183
[TBL] [Abstract][Full Text] [Related]
9. The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
Botticelli A; Cirillo A; Scagnoli S; Cerbelli B; Strigari L; Cortellini A; Pizzuti L; Vici P; De Galitiis F; Di Pietro FR; Cerbelli E; Ghidini M; D'Amati G; Della Rocca C; Mezi S; Gelibter A; Giusti R; Cortesi E; Ascierto PA; Nuti M; Marchetti P
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32353934
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.
Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Wu EQ
Exp Hematol Oncol; 2015; 4():31. PubMed ID: 26693096
[TBL] [Abstract][Full Text] [Related]
12. Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
Frost N; Tessmer A; Schmittel A; van Laak V; Raspe M; Ruwwe-Glösenkamp C; Brunn M; Senger C; Böhmer D; Ochsenreither S; Temmesfeld-Wollbrück B; Furth C; Schmidt B; Neudecker J; Rückert JC; Suttorp N; Witzenrath M; Grohé C
Lung Cancer; 2018 Nov; 125():164-173. PubMed ID: 30429016
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
Brieau B; Auzolle C; Pozet A; Tougeron D; Bouché O; Soibinet P; Coriat R; Prieux C; Lecomte T; Goujon G; Marthey L; Rougier P; Bonnetain F; Ducreux M; Taieb J; Zaanan A
Dig Liver Dis; 2016 Apr; 48(4):441-5. PubMed ID: 26775096
[TBL] [Abstract][Full Text] [Related]
14. Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study.
Zeng F; Lu T; Xie F; Chen L; Zhang L; Su Y; Yu Z; Xiao Y; Ao F; Li G; Chen Z; Gong X; Li J
Transl Oncol; 2021 Nov; 14(11):101187. PubMed ID: 34365221
[TBL] [Abstract][Full Text] [Related]
15. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.
Turkmen E; Erdogan B; Kodaz H; Hacibekiroglu I; Onal Y; Uzunoglu S; Kilic N; Cicin I
Acta Gastroenterol Belg; 2016; 79(2):211-5. PubMed ID: 27382940
[TBL] [Abstract][Full Text] [Related]
16. Metastatic gastric cancer: Does the site of metastasis make a difference?
Tan HL; Chia CS; Tan GHC; Choo SP; Tai DW; Chua CWL; Ng MCH; Soo KC; Teo MCC
Asia Pac J Clin Oncol; 2019 Feb; 15(1):10-17. PubMed ID: 29920947
[TBL] [Abstract][Full Text] [Related]
17. Radiation therapy on primary tumour of synchronous metastatic head and neck squamous cell carcinomas.
Tang É; Nguyen TV; Clatot F; Rambeau A; Johnson A; Sun XS; Tao Y; Thariat J
Cancer Radiother; 2020 Oct; 24(6-7):559-566. PubMed ID: 32753240
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
19. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
[TBL] [Abstract][Full Text] [Related]
20. Increasing survival of metastatic breast cancer through locoregional surgery.
Díaz de la Noval B; Frías Aldeguer L; Ángeles Leal García M; García López E; Díaz Almirón M; Herrera de la Muela M
Minerva Ginecol; 2018 Feb; 70(1):44-52. PubMed ID: 28994557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]